178 related articles for article (PubMed ID: 30094640)
1. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?
Soike MH; McTyre ER; Shah N; Puchalski RB; Holmes JA; Paulsson AK; Miller LD; Cramer CK; Lesser GJ; Strowd RE; Hinson WH; Mott RT; Johnson AJ; Lo HW; Laxton AW; Tatter SB; Debinski W; Chan MD
Neuroradiology; 2018 Oct; 60(10):1043-1051. PubMed ID: 30094640
[TBL] [Abstract][Full Text] [Related]
2. Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C; Capellades J; Pineda E; Estival A; Puig J; Domenech S; Verger E; Pujol T; Martinez-García M; Oleaga L; Velarde J; Mesia C; Fuentes R; Marruecos J; Del Barco S; Villà S; Carrato C; Gallego O; Gil-Gil M; Craven-Bartle J; Alameda F;
Cancer Med; 2017 Dec; 6(12):2858-2866. PubMed ID: 29105360
[TBL] [Abstract][Full Text] [Related]
3. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design.
Holmes JA; Paulsson AK; Page BR; Miller LD; Liu W; Xu J; Hinson WH; Lesser GJ; Laxton AW; Tatter SB; Debinski W; Chan MD
J Neurooncol; 2015 Sep; 124(3):447-53. PubMed ID: 26186902
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
5. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of glioblastoma multiforme in elderly patients: treatments, O-6-methylguanine-DNA methyltransferase (MGMT) methylation status and survival.
Abhinav K; Aquilina K; Gbejuade H; La M; Hopkins K; Iyer V
Clin Neurol Neurosurg; 2013 Aug; 115(8):1375-8. PubMed ID: 23333005
[TBL] [Abstract][Full Text] [Related]
7. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
8. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
[TBL] [Abstract][Full Text] [Related]
9. Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma.
Cui Y; Ren S; Tha KK; Wu J; Shirato H; Li R
Eur Radiol; 2017 Sep; 27(9):3583-3592. PubMed ID: 28168370
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
12. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
13. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
[TBL] [Abstract][Full Text] [Related]
14. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Younis SG; Khedr RA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O
Sharma M; Bellamkonda S; Mohapatra S; Meola A; Jia X; Mohammadi A; Angelov L; Barnett GH; Vogelbaum M; Ahluwalia MS
World Neurosurg; 2018 Aug; 116():e147-e161. PubMed ID: 29709748
[TBL] [Abstract][Full Text] [Related]
17. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
18. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
